Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Bristol-myers squibb company crawled time : 11:00 save search
AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS
Published: 2023-10-31 (Crawled : 11:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 4.66%
H: 0.0%
C: -3.51%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.25%
H: 0.54%
C: 0.29%
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: -0.41%
H: 2.1%
C: 1.11%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.61%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.33%
H: 0.92%
C: 0.61%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.14%
H: 0.68%
C: -0.32%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -2.77%
H: 0.6%
C: -0.07%
financial results
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
Published: 2023-10-23 (Crawled : 11:00) - globenewswire.com
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.19%
H: 0.66%
C: -0.62%
ADXS | $0.57 12.48% 9.5K
|
Health Technology
|
| O: 0.0%
H: 5.56%
C: 0.0%
al102 congress tumors pharmaceuticals trial results phase 2
Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients
Published: 2023-04-20 (Crawled : 11:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.23%
H: 0.16%
C: -0.24%
license cancer treatment agreement
Ulcerative Colitis Drug Global Market Report 2022: Increasing Prevalence of Ulcerative Colitis and Inflammatory Bowel Diseases Bolsters Sector
Published: 2023-04-07 (Crawled : 11:00) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
| Email alert
Add to watchlist
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
| Email alert
Add to watchlist
drug report global market
Evotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership
Published: 2023-03-28 (Crawled : 11:00) - biospace.com/
EVO | $7.15 -0.7% 19K
|
Manufacturing
|
| O: 1.56%
H: 3.58%
C: 3.58%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.01%
H: 0.75%
C: 0.18%
partnership
Cervical Cancer Drugs Global Market Research Report 2023 Featuring F. Hoffmann-La Roche, Hetero, GSK, Eli Lilly, Pfizer, Alnylam, Allergan, Biocon, Bristol-Myers Squibb, and Novartis
Published: 2023-02-24 (Crawled : 11:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -1.25%
H: 0.59%
C: 0.59%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.25%
H: 0.03%
C: -0.81%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.46%
H: 0.38%
C: -1.34%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.41%
H: 0.15%
C: -1.31%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.98%
H: 0.16%
C: -0.55%
research global report novartis cancer market
Synthetic Small Molecule API Market to Reach $217.96 Billion by 2030
Published: 2022-12-13 (Crawled : 11:00) - prnewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: 10.29%
H: 0.0%
C: 0.0%
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 1.89%
H: 0.88%
C: -0.09%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.6%
H: 0.0%
C: -2.53%
ALB | $112.15 0.31% -0.13% 2M
|
Process Industries
|
| O: 3.66%
H: 0.06%
C: -2.58%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.99%
H: 0.33%
C: -1.29%
market
Global $16.4B Colorectal Cancer Drugs Market Outlook, 2026 - Diagnosed Incident Cases Expected to Increase by 27.3%, to 672,400 Cases by 2037
Published: 2022-07-12 (Crawled : 11:00) - prnewswire.com
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.17%
H: 0.7%
C: -0.56%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.36%
H: 1.72%
C: -0.18%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.33%
H: 0.0%
C: 0.0%
expected cancer market
A $41.8 Billion Global Opportunity for Small Molecule Drug Discovery by 2026 - New Research from StrategyR
Published: 2022-07-04 (Crawled : 11:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
| Email alert
Add to watchlist
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
| Email alert
Add to watchlist
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
| Email alert
Add to watchlist
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
| Email alert
Add to watchlist
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
| Email alert
Add to watchlist
drug research
Global Axial Spondyloarthritis Market Research Repoirt 2022: Biopharmaceutical Companies are Trying to Match Themselves with New Technologies in the Market to Improve the Overall System
Published: 2022-06-14 (Crawled : 11:00) - prnewswire.com
UCBJY | $63.676 -4.38% 7.2K
|
Manufacturing
|
| O: -0.22%
H: 0.0%
C: -1.02%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -2.24%
H: 0.0%
C: 0.0%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.43%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.49%
H: 0.98%
C: 0.56%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.4%
H: 0.33%
C: -0.91%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -1.04%
H: 0.87%
C: -1.31%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.41%
H: 0.73%
C: -0.54%
research system companies market
Intensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Ipilimumab in Patients with Relapsed, Refractory, Metastatic Sarcomas
Published: 2022-06-02 (Crawled : 11:00) - prnewswire.com
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
int230
Head and Neck Cancer Market worth $ 9.07 Billion by 2030 - Exclusive Report by InsightAce Analytic
Published: 2022-03-23 (Crawled : 11:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 3.81%
H: 0.0%
C: -0.44%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -4.55%
H: 6.28%
C: 6.28%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -1.94%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.87%
H: 0.0%
C: 0.0%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.55%
H: 0.0%
C: 0.0%
MGNX | $15.62 -2.8% -2.88% 1M
|
Health Technology
|
| O: -1.31%
H: 3.88%
C: -0.67%
KURA | $17.55 -0.74% -0.74% 1.3M
|
Health Technology
|
| O: -1.34%
H: 0.12%
C: -2.6%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.04%
H: 0.08%
C: -1.26%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.31%
H: 1.85%
C: 1.55%
ADXS | $0.57 12.48% 9.5K
|
Health Technology
|
| O: -1.64%
H: 8.33%
C: 0.0%
CVM | $1.56 4.0% 0.0% 230K
|
Health Technology
|
| O: -0.92%
H: 2.31%
C: -3.47%
report cancer market
Hematological Malignancies Drugs Market worth $ 42.78 Billion by 2030 - Exclusive Report by InsightAce Analytic
Published: 2022-03-08 (Crawled : 11:00) - prnewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: -0.14%
H: 5.36%
C: 5.36%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -2.75%
H: 0.28%
C: -1.04%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.38%
H: 1.81%
C: 0.28%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -1.55%
H: 0.71%
C: -0.28%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.29%
H: 0.6%
C: -1.24%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 3.03%
H: 0.0%
C: 0.0%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 1.4%
H: 0.7%
C: -1.15%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: -0.3%
H: 3.38%
C: 0.32%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.35%
H: 0.0%
C: 0.0%
ema drug report
Telecare Market Size Worth $6.3 Billion by 2030 | CAGR: 5.7%: Grand View Research, Inc.
Published: 2022-02-28 (Crawled : 11:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -3.4%
H: 7.54%
C: 7.54%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 0.54%
H: 0.07%
C: -3.85%
TDOC S | $12.98 -1.52% 0.08% 5.3M
|
Health Services
|
| O: 12.54%
H: 0.36%
C: -4.65%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 1.92%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.21%
H: 0.0%
C: 0.0%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.07%
H: 1.49%
C: 1.45%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 1.66%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 2.51%
H: 0.32%
C: 0.1%
research
Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021
Published: 2021-12-02 (Crawled : 11:00) - globenewswire.com
BOLT | $1.12 -1.75% -1.79% 55K
|
|
| O: 3.22%
H: 8.6%
C: 6.35%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 2.17%
H: 0.0%
C: 0.0%
trial therapeutics phase 1 iot
Evotec Reaches Programme Designations in Neuroscience Collaboration with Bristol Myers Squibb
Published: 2021-11-10 (Crawled : 11:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.27%
H: 1.09%
C: 0.15%
collaboration designation
TCR² Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo® and Yervoy® in Mesothelin-Expressing Solid Tumors
Published: 2021-10-25 (Crawled : 11:00) - globenewswire.com
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.08%
H: 0.77%
C: 0.16%
TCRR 4 | $1.48 3.38% 3.9M
|
Health Technology
|
| O: -0.88%
H: 1.92%
C: 0.88%
solid tumors collaboration trial cel
WuXi STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland
Published: 2021-08-03 (Crawled : 11:00) - prnewswire.com
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.41%
H: 1.51%
C: 1.48%
acquisition switzerland
Global Colorectal Cancer Drugs Markets Report 2021-2030: VEGF Inhibitors, EGFR Inhibitors, BRAF or MEK Inhibitors, TKI Inhibitors, Immunomodulators, PD1/PDL1 Inhibitors
Published: 2021-07-09 (Crawled : 11:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.71%
H: 1.44%
C: 0.2%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.01%
H: 1.3%
C: 0.69%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 0.31%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.0%
H: 0.0%
C: 0.0%
cancer colorectal cancer drug
Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia
Published: 2021-06-11 (Crawled : 11:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.74%
H: 0.07%
C: -0.81%
phase 2 results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.